Paracrine Inc CEO Christopher Calhoun joined Proactive New York to speak about the San Diego, California-based group's aim to treat unmet needs in healthcare including diabetic foot ulcers, heart failure, and hand dysfunction using its autologous cell therapy platform.
Calhoun says the privately-held group is moving into a Series A round to fund its clinical pipeline, with data he says it already owns through its acquisition of what was once known as Cytori Therapeutics. It aims to begin clinical trials in 1Q of 2022.